Product
Rotigotine
Aliases
Neupro
Name
Neupro
INN Name
rotigotine
FDA Approved
Yes
4 clinical trials
1 organization
3 indications
1 document
Indication
restless legs syndromeIndication
Parkinson's diseaseIndication
Kidney DiseasesClinical trial
A Remote, Double-Blind, Randomized, Placebo-Controlled Study of Rotigotine Transdermal System in Adolescent Subjects With Idiopathic Restless Legs SyndromeStatus: Terminated, Estimated PCD: 2022-07-25
Clinical trial
A Remote, Open-Label, Long-Term, Follow-up Study to Determine the Safety, Tolerability, and Efficacy of Rotigotine Transdermal System as Monotherapy in Adolescents With Restless Legs SyndromeStatus: Terminated, Estimated PCD: 2022-09-01
Clinical trial
Comparative, Randomized, Open, Crossover Clinical Trial to Investigate Adhesiveness of a Newly Developed Rotigotine-containing Transdermal Patch in Patients With Parkinson's DiseaseStatus: Completed, Estimated PCD: 2021-10-30
Clinical trial
Safety of RotigotiNe in Patients With Autosomal Dominant Polycystic Kidney DiseaseStatus: Not yet recruiting, Estimated PCD: 2029-05-01
Document
DailyMed Label: NeuproOrganization
UCB, Inc.